Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.

Medication nonadherence may lead to treatment escalation in children with UC

03 Nov 2019

In paediatric patients with ulcerative colitis (UC), nonadherence to mesalazine negatively affects its therapeutic efficacy and may, in turn, result in treatment escalation, according to data from PROTECT.

PROTECT included 268 newly diagnosed paediatric UC patients (mean age, 12.3 years; 50 percent female). All patients received standardized mesalazine, with pre‐established criteria for escalation to thiopurines or anti‐tumour necrosis factor alpha (TNFα inhibitors). Adherence was monitored using pill bottles with electronic caps.

Researchers examined whether longitudinal adherence to treatment was associated with steroid‐free remission at week 52 (defined as quiescent disease on mesalazine alone with no corticosteroids ≥4 weeks prior) and need for treatment escalation (defined as introduction of immunomodulators, calcineurin‐inhibitors or anti‐TNFα inhibitors).

Results revealed that average mesalazine adherence trajectories were not predictive of steroid‐free remission at week 52. On the other hand, declining adherence over time (adherence rate of ≤85.7 percent at month 6) showed a strong association with treatment escalation (p=0.001).

According to the researchers, the present data highlight the importance of targeting adherence difficulties early in the disease course to reduce the likelihood of the need for treatment escalation in this population. They also stressed that treatment escalation is not based on suboptimal adherence to maintenance medication, but rather on disease response (or lack of response) to maintenance medication.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Oct 2019
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
03 Oct 2019
Early enteral nutrition (EEN) speeds up the recovery of gastrointestinal function after laparoscopic common bile duct exploration (LCBDE), according to a study. However, EEN also increases complications such as diarrhoea and abdominal distension.
01 Sep 2019
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
26 Sep 2019
Use of proton pump inhibitors contributes to increased risk of cholangitis, a large cohort study suggests.